COVID-19 -- United Kingdom
Abstract
--------
Background
Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (COVID-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.
Methods
In this multicenter, placebo-controlled, phase 1-2a trial, we randomly assigned healthy
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?8104986&promed&0
No comments:
Post a Comment